Etiology and management of cholangitis in pediatric liver transplant recipients: a systematic review Authors: Alizée Hof, Robin Rey, Nathalie Rock, Arnaud G L’Huillier Published: 2026 ABSTRACT AbstractPurpose of reviewChildren undergoing liver transplantation are highly vulnerable to infections. Cholangitis is a potential post-transplant complication requiring broad-spectrum anti-infective therapy, raising concerns about antimicrobial resistance in this immunosuppressed population. We conducted a systematic review to evaluate antimicrobial management of post-transplant cholangitis in pediatric patients.Recent findingsNine heterogeneous studies were included. Definitions of cholangitis varied widely, combining clinical, laboratory, imaging, and microbiological criteria, highlighting the need for standardization. Gram-negative bacteria predominated, particularly Klebsiella spp., Pseudomonas aeruginosa, and Escherichia coli. Prophylaxis commonly relied on broad-spectrum antibiotics, and initial treatment was empirical in all studies, with occasional adjustment based on microbiological results. First-line therapies included piperacillin–tazobactam and third-generation cephalosporins. Second-line regimens involved agents from various antibiotic classes, including glycopeptides, lipopeptides, aminoglycosides, and fluoroquinolones, as well as antifungals. Meropenem was used as either first-line or second-line therapy.SummaryImproved characterization and standardized reporting of pathogens and treatments are needed to guide targeted antimicrobial strategies and limit multidrug-resistant organisms. More detailed and harmonized data reporting is essential to optimize management of post-transplant cholangitis in children.Keywords: cholangitis, liver transplant, pediatric, treatment INTRODUCTION Liver transplantation is a life-saving therapeutic option for children with end-stage liver disease. Biliary atresia is the most common indication for pediatric liver transplantation (PLT; approximately 50%), followed by metabolic disorders (15%), fulminant hepatitis, cholestatic disorders (e.g. Alagille syndrome, progressive familial intrahepatic cholestasis), and malignancies [1,2]. Pediatric liver transplant recipients are vulnerable to infections due to multiple factors such as immunosuppression, long hospitalization, indwelling catheters, and procedures such as surgery and post-transplant cholangiography for bile drainage [3,4]. Despite significant advances in surgical technique, perioperative care and antimicrobial prophylaxis, infectious complications remain a major source of morbidity and mortality in pediatric liver transplant recipients, accounting for half of death in the immediate postoperative period [3,5]. Among infectious complications, the incidence of post-transplant cholangitis ranges from 1 to 10%, depending on the type of biliary reconstruction [6]. Cholangitis results from biliary obstruction or stasis, which facilitate the ascent of enteric pathogens into the biliary tree. Clinical manifestations are ranging from mild cholangitis to severe sepsis or septic shock, and they may also compromise graft function [7]. Management of post-transplant cholangitis involves the use of broad-spectrum anti-infective agents to cover the most common pathogens such as Escherichia coli, Klebsiella spp., Enterococcus spp., and Pseudomonas aeruginosa [4,8,9]. However, this empiric approach has raised concerns regarding antimicrobial resistance, especially in immunosuppressed hosts who are particularly at risk for multidrug-resistant organisms because of their increased healthcare exposure, their limited ability to clear infections, and their more frequent exposure to antibiotics. Therefore, optimizing anti-infective strategies requires a balance between adequate empiric coverage and antimicrobial stewardship. To our knowledge, no systematic review nor guidelines exist on the antimicrobial management of post-transplant cholangitis in children. The present systematic review aims to examine the antimicrobial management of acute cholangitis following pediatric liver transplantation by identifying the most common etiologic agents and describing empiric and targeted anti-infective strategies used in this context. no caption available MATERIALS AND METHODS This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (checklist is available in Supplementary Material 3. Literature search Literature search was done using PubMed, Embase, and Web of Science databases in December 2025, using the keywords ‘Pediatric’, ‘Liver transplant’, ‘Cholangitis’, ‘Anti-infective treatment,’ and their relevant synonyms combined with Boolean operators, adapted to the syntax and indexing of each database. The complete search strategy is available in Supplementary Material 1. Studies describing the anti-infective treatment of acute cholangitis in liver transplant recipients aged less than 18 years were included. Items were excluded if the article was not available, or in case of informal publication (letter, commentary, editorial, abstract only). No restrictions in terms of language, year of publication, or study design were applied. First, one reviewer (A.H.) screened all articles by title and abstract. Then, two reviewers independently (A.H. and R.R.) screened the remaining articles’ full texts and reached consensus on the final set of included studies. Two other reviewers (N.R. and A.L.) resolved uncertainties regarding article selection at the final stage of the process. Data Data were extracted using a predefined form that captured article characteristics (authors, year of publication), study design and population (age, indication for liver transplant, biliopathy, definition of cholangitis), post-transplant antibioprophylaxis, pathogens and source of infection described, anti-infective agents used, and time between liver transplant and cholangitis. When available, details on the route of administration, duration, and dosage of treatment were also retrieved. Some authors were contacted for additional data, information or details regarding their publications. Risk of bias and synthesis The risk of bias was assessed by two reviewers (A.H. and R.R.) using the Newcastle–Ottawa Scale (NOS) for cohort studies and the Joanna Briggs Institute (JBI) Critical Appraisal tool for case report and case series. No meta-analysis was done and findings for all the outcomes of interest are presented in descriptive tables. The risk of bias is presented in tables for each individual study. RESULTS Study selection A total of 1495 publications were identified across the three databases. After removing 219 duplicates, 1167 were excluded during title and abstract screening, and 100 after full text review, resulting in nine studies included in the final selection (Fig. 1). PRISMA flow diagram. LT, liver transplantation. Study characteristics The characteristics of the included studies are summarized in Table 1 and in Supplementary Material 2. All included studies were published between 2016 and 2025. Of the nine studies, seven were retrospective [10–16], one was a case series [17], and one was a case report [18]. Total cohort sizes ranged from 27 to 210 patients, with the number of PLT recipients varying widely (from 2 to 188 patients). The number of cholangitis episodes reported per study ranged from 7 to 43. Median or mean age of children reported in these studies mostly ranged between 2 and 5 years. Among studies reporting indication for liver transplantation, biliary atresia was the most common diagnosis in four of seven studies [10–13]. Other frequent indications included genetic disorders, hepatitis, and oncologic disorders. Two studies did not report indication for liver transplantation [15,17]. Table 1Characteristics of the included studiesNumberAuthor;design; yearPopulation; ageIndication for liver transplantDefinition of cholangitisTime since LT; type of culturePathogens (by frequence)AntibioprophylaxisAnti-infective agents1Ashkenazi-Hoffnung et al.Retrospective study; 2016PLT: 44hospitalization for fever: 133 episodes post-transplantCholangitis among the hospitalizations: 28Whole cohort:Biliary atresia: 27Hepatitis: 6Genetic disorder: 9Oncologic disorder: 0Other: 2(A) signs of systemic inflammation(B) signs of cholestasis(C) imaging (biliary tract dilatation and/or evidence of etiology on imaging)Suspected: (A) and [(B) or (C)]Confirmed: (A) and (B) and (C)Whole cohort: <1 month: 31 month–1 year: 391–5 years: 58> 5 years: 33Cholangitis:E. coli: 3 including MDR: 2Enterobacter spp.: 1Enterococcus spp.: 1E. coli and Klesbiella spp.: 1Klesbiella and Enterococcus spp.: 1Pseudomonas and Enteroccocus spp.: 1Unknown: 20Prophylaxis post LT:piperacillin/tazobactam and gentamicinEmpirical antibiotic treatment for all cholangitis*Whole cohort:Median (SD): 4.7 (5.07) years at admissionBlood2Lin et al.Retrospective study; 2016PLT: 188Post-transplant cholangitis (nonsuppurative): 9Among PLT cholangitis:Biliary atresia: 6Other: 3Histology (non-suppurative cholangitis): increased bile ductule profiles at the edges of portal tracts, bile plugs within ductules, paucity of acute inflammation in portal tracts, and normal numbers of interlobular bile duct profiles with nonreactive morphology*Whole cohort:Mean (SD): 0.9 months (0.59 months) between LT and biopsyWhole cohort:P. aeruginosaK. pneumoniaeEnterococcus spp.Bacteroides sppCitrobacter spp.S. aureus S. pneumoniaeC. albicans(NI about frequency)NIAntibiotic treatment*Cholangitis cases:Mean (SD): 5.6 (5.4) yearsBloodBodyfluidsWoundsPusLines3Sansotta et al.Retrospective study; 2021PLT: 50PTC post-PLT: 157Post-transplant cholangitis after PTC: 70Whole cohort:Biliary atresia: 33Genetic disorders: 7Other: 10(A) Fever (>38.5°C)(B) Elevated inflammatory markers after PTCDefined as: (A) and (B)NIWhole cohort:E. faecium: 15 includingVRE: 3P. aeruginosa: 10E. coli: 5 including ESBL: 2 and KPC: 1K. pneumoniae: 4 including ESBL: 2C. albicans: 4S. aureus: 2E. aerogenes: 2 includingESBL: 2E. faecalis: 2E. cloacae: 1 includingESBL: 1A. baumanii: 11st line in PTC (n = 135): cefotaxime: 73piperacillin-tazobactam: 46ciprofloxacin: 162nd line in PTC (n = 22*):meropenemdaptomycinvancomycinAntibiotherapy continued after 115/157 procedures (70/115 for cholangitis)1st line: 81/115*2nd-line (34/115):vancomycin: 13meropenem: 10daptomycin and/or linezolid: 6aminoglycosides: 4fluconazole and micafungin: 2Whole cohort:Median (IQR): 3.05 (3–9) years at PTCBlood performed 70/70 of cholangitis, positive in 15/70Bile: 30/70 of cholangitis, positive in 20/304Soria-Navarroa et al.Retrospective study; 2022Children: 37 including26 PLTNSBTM: 113, including 77 after PLT Cholangitis (pre- and post-transplant): 27Cholangitis (among PLT): 7 episodes (in 5 patients) **Among PLT:Biliary atresia: 11Oncologic disorder: 5Others: 10(A) systemic inflammation(B) cholestasis(C) imaging abnormalities (biliary dilatation or evidence of its cause)Defined as: (A) and (B) and (C)PLT subgroup:Median (IQR): 8 months (2 months to 2 years) between LT and procedureNSBMT-related infections:Enteroccocus spp.: 12Klesbiella spp.: 9E. cloacae: 4P. aeruginosa: 4S. maltophilia: 4Candida spp.: 3E. coli: 2C. freundii: 1Cholangitis among PLT: **P. aeruginosa: 1E. coli and E. faecium: 1ESBL-producing K. pneumoniae: 2AmpC-producing K. oxytoca: 1E. faecalis: 1Periprocedural prophylaxis (no infection at time of procedure, n = 69): piperacillin-tazobactam: 53meropenem: 9cefoxitin: 2ciprofloxacin: 1Antibiotic treatment for infection duringNSBTM (n = 44): piperacillin–tazobactam 16meropenem 13combined antibiotherapy* 12Cholangitis among PLT: **Empirical treatment: piperacillin-tazobactamTargeted treatment:meropenem or ertapenem (for ESBL), teicoplanin (for E. faecium), piperacillin-tazobactam in case of negative culturesWhole cohort:Median (IQR): 4 (1–8)years at time of NSBTMBlood in 29/32NSBMT-related infections, positive in 9/29(polymicrobial in 2/9)Bile in 18/32 NSBMT-related infections, positive in 16/18(polymicrobial in 9/16)Blood in 7/7 PLT cholangitis, positive in 3/7**Bile in 5/7 PLT cholangitis, positive in 5/5**5Ying et al.Retrospective study; 2020LT: 210Post-transplant infections: 196Post-transplant cholangitis: 43/196Whole cohort:Viral hepatitis: 139Inherited liver disease: 24Toxic related liver disease: 13Autoimmune liver diseases: 11Hepatocellular carcinoma: 11Cirrhosis: 3Others: 9(A) fever, right upper quadrant pain, and elevation of liver chemistry(B) evidence of cholangitis on liver biopsy(C) isolation of the same organism from drain and bloodDefined as: (A) and [(B) or (C)]Whole cohort:Time to infection (all infections combined):0–1 month post LT: 153/1961–3 months: 26/196 > 3 months: 17/196Cholangitis:S. maltophilia: 14%K. pneumoniae: 12%P. aeruginosa: 9%E. faecium: 9%Staphylococcus spp.: 7%Funghi*: 9%A. baumanii: 2%Prophylaxis post LT:based on donor situation and culture*Empirical treatment, then tailored based on susceptibility testing*Whole cohort:Median (range): 50 (0.6–69) years at transplantBlood cultureBile culture6Zhang et al.Retrospective study; 2018Children: 27 including2 PLTCholangitis: 27(surgery-related: 19; surgery-unrelated: 8)NI(A) fever(B) increased WBC/CRP(C) increased transaminases(D) bile sludge or gallstones observed by abdominal ultra sonographySuspected (after biliary atresia surgery): (A)Confirmed (after biliary atresia surgery or PLT): (A) and [(B) and/or (C)]Confirmed (no surgery): (A) and [(B) and/or (C)] and (D)NIWhole cohort:E. coli: 2K. pneumoniae: 1NI1st line: 3rd generation cephalosporin2nd line: meropenemWhole cohort:Range: 3 months–13 years *Blood7Işik et al.Retrospective study; 2024PLT: 155Neutropenia: 60 Cholangitis: 7 among the 60 neutropeniaNeutropenic group:Genetic disorder: 26Biliary atresia: 16Hepatitis: 6Oncologic disorder: 2Other: 10NININININeutropenia group:IV antibiotics: 60%oral antibiotics: 5%Neutropenia group:Mean (SD): 4.82 (4.93) yearsBlood8Garcia-Boyano et al.Case series; 2024Children treated with CZA: 18PLT: 8Cholangitis: unclearNININIWhole cohort:K. pneumoniae: 16 including OXA48: 15P. aeruginosa: 1NIInitial treatment (whole cohort):Meropenem and amikacin: 6Meropenem: 2Piperacillin–tazobactam: 2Meropenem and ceftazidime: 1Meropenem and levofloxacin: 1All patients eventually treated with CZAWhole cohort:Median (IQR): 21 (10–43) months Range: 87 days - 15.4 years) at treatment onsetBloodBileAsciticfluid9Odenthal et al.Case report; 20251HepatoblastomaClinical status: jaundice, pruritus, cholic stoolsLaboratory: transaminases, gamma-GT, bilirubinUltrasound: intra and extrahepatic biliary ducts dilatation7 months between LT and initial PTC; follow-up PTC performed 6 months after initial oneNINIMeropenem5 years(*) Not otherwise specified; (**) additional information provided by the authors upon request; A., Acinetobacter; C., Citrobacter; CZA, ceftazidime–avibactam; E. coli, Escherichia coli; E., Enterococcus; ESBL, extended spectrum beta-lactamase producer; IQR, interquartile range; IV, intravenous; K., Klebsiella; KPC, Klebsiella pneumoniae carbapenemase; LT, liver transplantation; MDR, multi-drug resistant; NI, no information; NSBTM, nonsurgical manipulation of the biliary tract; OXA-48, Oxacillinase-48; P., Pseudomonas; PLT, pediatric liver transplantation; PTC, percutaneous transhepatic cholangiography; S., Staphylococcus; SD, standard deviation; VRE, vancomycin-resistant Enterococcus. Characteristics of the included studies (*) Not otherwise specified; (**) additional information provided by the authors upon request; A., Acinetobacter; C., Citrobacter; CZA, ceftazidime–avibactam; E. coli, Escherichia coli; E., Enterococcus; ESBL, extended spectrum beta-lactamase producer; IQR, interquartile range; IV, intravenous; K., Klebsiella; KPC, Klebsiella pneumoniae carbapenemase; LT, liver transplantation; MDR, multi-drug resistant; NI, no information; NSBTM, nonsurgical manipulation of the biliary tract; OXA-48, Oxacillinase-48; P., Pseudomonas; PLT, pediatric liver transplantation; PTC, percutaneous transhepatic cholangiography; S., Staphylococcus; SD, standard deviation; VRE, vancomycin-resistant Enterococcus. Definition of cholangitis definition and time between transplantation and infection The definition of cholangitis varied across studies but generally required a combination of clinical, laboratory, imaging, and/or microbiological criteria. Most articles (4/9 studies) relied on three parameters [10,13,15,18]: systemic inflammation (defined by fever, chills, elevated white blood cell count or elevated C-reactive protein); cholestasis (defined by jaundice or abnormality of the liver function tests); and biliary abnormalities on imaging (intrahepatic and/or extrahepatic bile duct dilatation). One study defined cholangitis based on histological criteria (non-suppurative cholangitis) [11], another based on fever and elevated inflammatory markers [12], and one study required microbiological confirmation of pathogens in addition to clinical criteria [14]. Two articles did not provide a definition of cholangitis [16,17]. The time between liver transplantation and cholangitis was highly heterogeneous but a vast majority of infections occurred in the first year following liver transplantation or after a liver-related procedure (e.g. percutaneous transhepatic cholangiography [PTC] or endoscopic transpapillary procedures [ETP]). Pathogens Pathogen identification relied primarily on blood cultures in eight of nine studies [10–17], obtained in cases of suspected cholangitis. Four studies additionally used bile culture for pathogen identification [12–14,17], while two studies also included cultures from ascitic fluid as well as from wounds, pus, and intravascular lines [11,17], not specific to cholangitis but to infections overall. Pathogens were not consistently documented and when documented, discrimination between cholangitis and other infections were not necessarily provided at the pathogen level, only two studies [10,13] reported specifically germs identified in PLT cholangitis. In these two studies [10,13], Gram-negative bacteria were most frequently identified, especially Klebsiella spp., P. aeruginosa, E. coli, and Enterobacter spp., while Gram-positive bacteria were less frequent and mainly included Enterococcus spp. such as Enterococcus faecium and Enterococcus faecalis. Antimicrobial prophylaxis and treatment Three studies reported antibiotic prophylaxis: two addressed periprocedural prophylaxis (PTC and ETP) [12,13], and one described prophylaxis following liver transplantation [10]. Prophylactic regimens mainly involved broad-spectrum antibiotics, including piperacillin–tazobactam, third-generation cephalosporins, carbapenems, and ceftazidime–avibactam. Initial antibiotic management of cholangitis was empirical in all studies. Five studies reported adaptation of therapy according to microbiological results [12–15,17]. First-line treatment included piperacillin–tazobactam [13], third-generation cephalosporins [15], meropenem [18], or any of these three agents [17]. Second-line therapies comprised vancomycin, daptomycin, amikacin, linezolid, ceftazidime or levofloxacin, meropenem, and antifungal agents. None of the included studies reported the rate of cholangitis resolution or mortality attributable to post-transplant cholangitis, precluding any analysis of these outcomes. Risk of bias The overall risk-of-bias assessment is presented in Table 2. The main limitation identified in the majority of studies (six of seven studies) [10–16] concerned the comparability domain, as study designs did not allow comparison with non-exposed or healthy cohorts, nor did they adequately adjust for confounders when analyzing risk factors for infection or cholangitis after liver transplantation. In addition, Table 3 summarizes the principal limitations of the included studies in relation to our research question, particularly the limited reporting of pathogens and anti-infective treatments specific to cholangitis in PLT recipients. Table 2Risk-of-bias assessment of the included studies, with the Newcastle–Ottawa Scale for retrospective studies and Joanna Briggs Institute Critical Appraisal tool for case report and case seriesNewcastle–Ottawa ScaleSelection (0–4)Comparability (0–2)Exposure (0–3)Total (0–9)1/Ashkenazi-Hoffnung et al.☆☆☆☆☆5/92/Lin et al.☆☆☆☆☆☆6/93/Sansotta et al.☆☆☆☆☆5/94/Soria-Navarroa et al.☆☆☆☆☆☆☆☆8/95/Ying et al.☆☆☆☆☆5/96/Zhang et al.☆☆☆☆☆5/97/Işik et al.☆☆☆☆☆☆6/9Joanna Briggs Institute Critical Appraisal toolResponses to questionsYesUnclearNoOverall8/Garcia-Boyano et al.9/101/100/10Good9/Odenthal et al.6/82/80/8Good Risk-of-bias assessment of the included studies, with the Newcastle–Ottawa Scale for retrospective studies and Joanna Briggs Institute Critical Appraisal tool for case report and case series Table 3Limits of the included studies for the research objectives of this systematic reviewPathogenTreatmentNumber/authorCholangitis vs. otherLT vs. no LTCholangitis vs. otherLT vs. no LTOthers1/Ashkenazi-Hoffnung et al.SSSSAntibiotic treatment not specified2/Lin et al.USSSAntibiotic treatment not specifiedPathogen frequency not reportedIndication for PLT unclear3/Sansotta et al.USUSFirst-line antibiotic treatment not specified4/Soria-Navarroa et al.S**S**S**S**5/Ying et al.USUSNo discrimination regarding pathogens or treatment between pediatric vs. adult LT recipientsAntibiotic treatment not specified6/Zhang et al.UUUUIndication for PLT unclearAge of the population unclearFew pathogens reported7/Işik et al.––USAntibiotic treatment not specifiedPathogen frequency not reportedCholangitis definition unclearSelection bias (neutropenic infections only)8/Garcia-Boyano et al.UUUUIndication for PLT unclearCholangitis definition unclearSelection bias (patients treated with CZA)9/Odenthal et al.––SSNo pathogen identified(**) Additional information provided by the authors upon request. CZA, ceftazidim–avibactam; S, specified; U, unspecified. Limits of the included studies for the research objectives of this systematic review (**) Additional information provided by the authors upon request. CZA, ceftazidim–avibactam; S, specified; U, unspecified. DISCUSSION To our knowledge, this is the first systematic review focusing on the etiology and management of cholangitis following PLT. Even though almost 1500 articles were screened, very few articles could be included in the review, confirming the paucity of data on the topic and the heterogeneity of the included studies in terms of population, cholangitis definitions, pathogens, and treatment. Unlike the recently proposed definition of cholangitis following Kasai hepatoportoenterostomy in biliary atresia, which included clinical and laboratory/imaging criteria [19,20], there is no standardized definition of post-transplant cholangitis in either the pediatric or adult population. Most included articles in our review defined cholangitis as a triad of systemic inflammation, cholestasis, and biliary abnormalities on imaging [10,13,15,18]. A standardized definition of cholangitis following PLT would allow consistent identification, reporting, and management of this relatively rare condition across studies and settings. The age of reported pediatric cohorts varied between 2 and 5 years, suggesting that cholangitis occurs more frequently in infants and in the first years following liver transplantation, which is probably multifactorial. First, post-transplant infections are more frequent in infants than older children [21], likely because of the immaturity of their immune system, the absence of pathogen-specific immunity at time of transplant. Second, the first year(s) following PLT are at highest risk of infection because of a high net state of immunosuppression, immune dysregulation [22]. Third, the frequency of cholangitis in infants is at least partially related to the fact that the most common indication for PLT is biliary atresia, a condition where children are usually transplanted around 1 year old [23]. In young children, direct choledocho-choledochal anastomosis is often not feasible, requiring a Roux-en-Y hepaticojejunostomy, which is associated with a higher risk of biliary anastomotic strictures and the need for subsequent interventions, and procedure at risk of infections. Unfortunately, the impact of procedures such as post-transplant cholangiography is not clearly defined across the studies included in this review even if PTC in PLT seem to have a high rate of infectious complication, including cholangitis [12,24]. Gram-negative bacteria were the most frequent pathogens identified, in particular E. coli, Klebsiella spp. and P. aeruginosa. This is in line with previous data showing that in adult liver transplant recipients with infectious complications including cholangitis, E. coli, P. aeruginosa, K. pneumoniae, and E. faecium are the most frequent germs identified [25–27]. Culture of biological specimens play a crucial role in pathogen identification by allowing a step-down to a more targeted anti-infective therapy. In our systematic review, blood cultures were performed systematically in eight of the included studies, reflecting the relatively non-invasive character of this procedure. However the sensitivity of blood culture in our systematic review ranged between 21 and 43% [12,13] for the diagnosis of cholangitis when reported. In contrast, bile culture had a substantially higher sensitivity in our review, ranging between 67 and 100% when reported [12,13]. They were, however, performed in less than half of the studies, reflecting the challenge to obtain bile culture in the absence of indwelling drains. The difference in sensitivity between blood and bile culture for the diagnosis of cholangitis is in line with data showing a positive rate of blood and bile cultures of 35% and 85%, respectively in the general population affected by cholangitis [28]. However, bile culture results should be interpreted with caution as the colonization of indwelling bile drains can be associated with false-positive results. Antibiotic treatment for cholangitis was initiated empirically across studies and adapted according to microbiological identification whenever available. The frequent use of broad-spectrum antibiotics both for prophylaxis and for treatment of cholangitis likely reflect a combination of limited pathogen-specific data, and concerns for severe complications in these vulnerable patients. Interestingly, duration of antimicrobial treatment for cholangitis was rarely reported. The absence of evidence regarding optimal antimicrobial regimen and duration confirms the need for a standardized definition to allow for comparability between centers and consequently generate robust data through dedicated studies, which could enable more tailored antimicrobial strategies, maintaining clinical efficacy while potentially limiting the emergence of drug resistance. This study had several limitations. First, the number of included studies was limited. Second, pathogen frequency was commonly not reported. Third, discrimination of pathogens and/or antimicrobial treatment was commonly not performed between cholangitis and other infections, as well as between transplanted and non-transplanted (pediatric) patients. Then, anti-infective agents were insufficiently described, especially regarding length, posology, and route of administration. Finally, several studies were restricted to specific subgroups like neutropenic patients or patients treated with specific molecules. CONCLUSION This systematic review underscores the limited and heterogeneous evidence on etiology and antimicrobial management of cholangitis following PLT. Standardized definitions are urgently needed generate more evidence regarding antimicrobial regimen and duration in this vulnerable population. Acknowledgements None. Financial support and sponsorship None. Conflicts of interest There are no conflicts of interest. Supplementary Material Footnotes Supplemental digital content is available for this article. REFERENCES AND RECOMMENDED READING Papers of particular interest, published within the annual period of review, have been highlighted as: ▪ of special interest ▪ of special interest ▪▪ of outstanding interest ▪▪ of outstanding interest REFERENCES